Etrumadenant
- Generic Name
- Etrumadenant
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22N8O
- CAS Number
- 2239273-34-6
- Unique Ingredient Identifier
- W0ZE0NT8IF
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Phase 1
Completed
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 341
- Registration Number
- NCT03193190
- Locations
- 🇺🇸
Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath